UI Hospitals and Clinics

Clinical Trial Details

Short Title
A Study of ALT-801 in Patients with Relapsed or Refractory Multiple Myeloma
Official Title

A Study of ALT-801 in Patients with Relapsed or Refractory Multiple Myeloma

Description

Participants in this research study have been diagnosed with a type of multiple myeloma that has grown or spread and cannot be cured by surgery, radiation or any other conventional therapies. The purpose of this research study is to identify the side effects of the study drug, ALT-801, in patients with multiple myeloma, and to find out how safe it is, and how well it is tolerated. Investigators also wish to find out if the study drug can slow the progression of the disease and/or reduce the size of the tumors.

Start Date
August 9, 2012
End Date
January 2, 2014
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Raymond Hohl, MD, PhD
Contact Info

Karen Parrott, 319-353-6347

Department
Department or Field of Study
Keywords
ALT-801 ; cancer ; hohl ; IRB#201202504 ; multiple myeloma ; phase 1 ; phase 2 ; phase I ; phase II ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.